• Sponsored Content

Your Success to IND and BLA, Faster and Better

BPI Staff

July 19, 2019

1 Min Read

2019-BIO-Theater-samsung-300x160.pngIn this BPI Theater at BIO presentation, delivered on Wednesday, 5 June 2019, Eun Young Yang, executive director and head of the CSO business team at Samsung Biologics, explained how the firm’s end-to-end service increases the chance of commercial success for investigational new drugs (INDs). In addition to fully integrated development and manufacturing services for IND filing, Samsung offers regulatory expertise that can usher sponsoring organizations through clinical trials for monoclonal antibodies (MAbs), fusion proteins, bispecific antibodies, and multispecific antibodies — as well as
other difficult-to-develop molecule types.

You May Also Like